Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 USD | -1.58% | -8.47% | -26.36% |
30/04 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
27/03 | North American Morning Briefing : Stocks Edge -2- | DJ |
Sales 2022 | 9.01M 752M | Sales 2023 | 3.31M 276M | Capitalization | 48.89M 4.08B |
---|---|---|---|---|---|
Net income 2022 | -29M -2.42B | Net income 2023 | -8M -668M | EV / Sales 2022 | 2.06 x |
Net cash position 2022 | 4.17M 348M | Net cash position 2023 | 15.11M 1.26B | EV / Sales 2023 | 10.2 x |
P/E ratio 2022 |
-0.74
x | P/E ratio 2023 |
-5.88
x | Employees | 8 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.85% |
Latest transcript on Marker Therapeutics, Inc.
1 day | -1.58% | ||
1 week | -8.47% | ||
1 month | -5.81% | ||
3 months | -12.72% | ||
6 months | +68.75% | ||
Current year | -26.36% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 17/18/17 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 17/18/17 | |
Steven Elms
BRD | Director/Board Member | 60 | 06/19/06 |
Katharine Knobil
BRD | Director/Board Member | 60 | 08/21/08 |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 4.05 | -1.58% | 28,440 |
29/24/29 | 4.115 | -4.08% | 13,097 |
26/24/26 | 4.29 | -1.72% | 12,576 |
25/24/25 | 4.365 | -0.80% | 3,381 |
24/24/24 | 4.4 | -0.56% | 9,988 |
Delayed Quote Nasdaq, April 01, 2024 at 01:30 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
-26.36% | 36.1M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- MRKR Stock